Kornimate/medical-research-clean huggingface dataset:
marker for fai diagnosis

Conditions: Femoroacetabular Impingement

Summary: the diagnostic gold standard to differentiate fai (femural acetabular impingement) from other muscular-tendinous pathologies is, actually, the injection of intra-articular anesthetic (lidocaine), with a pre- and post- evaluation of pain scale. if, after injection, the pain disappears, the pain is probably due to an articular problem (fai). this kind of differential diagnosis test has a sensibility of 100% and a specificity of 81%. c-terminal telopeptide of type ii collagen (ctxii) as cartilage degradation index, could be a marker, simply detectable, to assess the healthy of the cartilage status and could be measured in serum and urine.

this study is observational-analytical and cross-sectional, because the same patient will receive both the diagnostic iter. for the rules of evidence-based medicine (brown et al., 2006), the definition of this study pico is: p (population)= all the patients with suspected fai afferent to orthopaedic-traumatology and prosthetic surgery and revisions of hip and knee implants i (intervention)= enzyme-linked immunosorbent assay (elisa) for c-terminal telopeptide of type ii collagen (ctxii) in serum and urine c (comparison)= intra-articular lidocaine injection o (outcome)= sensibility/specificity of elisa test from a literature analysis the c-terminal telopeptide of type ii collagen (ctxii) seem to be the best candidate for this kind of comparison. some previous studies (scarpellini et al, 2008) demonstrated that this marker could be used in this way, and, for this reason, the aim of this study is to investigate the sensibility and specificity of this marker in serum and urine, vs the actual diagnostic gold standard (anesthetic intra-articular injection). if the marker will be equal or better than the actual gold standard, the clinical practice will have an improvement, because this kind of analysis is simply performing and less invasive for the patient. the study will enroll 20 patients with suspected fai between 18-45 years and of both the gender.

Eligibility criteria:
inclusion criteria: * patients with clinical diagnosis of suspected fai * patients with clinical addressing to arthroscopy exclusion criteria: * patients referring articular rheumatic pathologies * patients referring traumatic events in hip * patients wearing other hip prosthesis
improving adherence to homework during therapy

Conditions: Anxiety; Depression; Depression/Anxiety

Summary: the purpose of this study is to expand adhere.ly- a simple, hipaa-compliant, web-based platform to help therapists engage clients in practicing therapeutic skills between sessions (homework) during mental health treatment by conducting a trial comparing standard therapy to therapy enhanced with adhere.ly.


Eligibility criteria:
inclusion criteria: providers: * english-speaking * mental health providers who have obtained at least a master's degree in social work, counseling, clinical psychology, or related field * carry active mental health treatment caseloads in the u.s. * have a laptop, tablet, or smartphone with internet access clients: * english-speaking * treatment-seeking adults ≥18 year * clinically elevated anxiety and depression as indicated by a score ≥10 on the gad-7 and/or phq-8 * have a laptop, tablet, or smartphone with internet access exclusion criteria: client with self-reported: * active psychotic symptoms (e.g., hallucinations, delusions) * significant cognitive disability, developmental delays, or pervasive developmental disorder.

Keywords: mhealth mental health adult mental health homework health technology
study of a polymorphism in patients with prostate cancer

Conditions: Prostate Cancer

Summary: rationale: studying samples of blood from patients with cancer and from healthy participants in the laboratory may help doctors learn more about changes that may occur in dna. purpose: this laboratory study is looking at blood samples from patients with prostate cancer and from healthy participants to identify a polymorphism that may help in the study of prostate cancer.

objectives: primary * determine the incidence of the d104n col18a1 polymorphism in patients with prostate cancer. secondary * determine the incidence of this polymorphism in african-american patients with prostate cancer. outline: this is a retrospective, multicenter study. dna is extracted from preexisting serum samples and polymerase chain reaction is performed to determine the genotype pattern. projected accrual: a total of 500 patients and 250 healthy participants will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of prostate cancer or healthy participant * patient enrolled on an irb-approved clinical trial at the national cancer institute or northwestern university, including, but not limited to, any of the following: * nci-99-c-0052 * nci-95-c-0178 * nci-00-c-003 * nci-00-c-0080 patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: recurrent prostate cancer stage i prostate cancer stage iib prostate cancer stage iia prostate cancer stage iii prostate cancer stage iv prostate cancer
brief intervention for alcohol use among injured patients

Conditions: Alcohol Drinking; Wounds and Injuries

Summary: the underlying hypothesis that providing brief interventions to individuals who engage in potentially harmful patterns of alcohol use will alter their drinking behavior and therefore avoid negative consequences. specifically, this study aims to determine if brief interventions will: 1. reduce the number of re-admissions and deaths due to injuries associated with alcohol consumption 2. reduce the number of driving under the influence (dui) arrests 3. reduce harmful drinking behavior

alcohol use is the most common underlying cause of injuries in the united states. there is a growing body of literature suggesting that brief interventions (bi), in the form of a short (10-60 minute) counseling session, may decrease alcohol consumption and its harmful consequences. in contrast to the abundant literature on the effectiveness of bi in the outpatient setting, only 3 randomized controlled trials have been performed an adults specifically in the setting of acute trauma, and have had inconclusive results. all three studies used highly trained persons to perform the bi, and all were greater than 30 minutes in duration, a situation that may not necessarily reflect the practicalities of routine medical care. this raises the question of whether the benefits seen in these studies reflect the expertise of a small number of individuals or whether the effects correlate with the amount of time spent with the patient. highly trained personnel and time are valuable commodities in a busy trauma center and may not be feasible given the competing clinical demands. we propose to investigate whether bi are effective in a setting that is more likely to reflect "real world" of clinical medicine rather than an idealized setting, utilizing trauma nurse practitioners to perform brief (5-10 minute) interviews. we will identify all patients admitted with trauma who test positive on a blood alcohol test. these patients will be consented and randomized to either a brief intervention group, or a standard medical care group. all patients will receive an audit questionnaire to identify patterns of drinking behavior and an alcohol information pamphlet. after discharge, patients will be telephoned at 1,6, and 12 months. the first 2 contacts will be to see how the patient is doing and to verify the contact information. the audit questionnaire will be re-administered during the 12 month interview.

Eligibility criteria:
inclusion criteria: * \>=18 yrs old * english or spanish speaking * mentally and physically able to provide consent and participate in the intervention * admission to the trauma ward or icu exclusion criteria: * \<18 yrs old * non-english or non-spanish speaking * severe psychiatric illness * incarcerated

Keywords: interviews brief intervention drinking alcohol injuries wounds intervention studies
early access program (eap) for avapritinib in patients with locally advanced unresectable or metastatic gist

Conditions: GIST

Summary: this is a us, multicenter, open-label expanded access program to provide access to avapritinib until such time that avapritinib becomes available through other mechanisms or the sponsor chooses to discontinue the program.


Eligibility criteria:
inclusion criteria: 1. patient is ≥ 16 years of age. 2. diagnosis of unresectable or metastatic gist 3. the patient is not eligible for an ongoing study of avapritinib or cannot access an ongoing study of avapritinib. 4. patient has received 3 or more tki therapies including imatinib, or the patient has gist that carries a mutation in exon 18 of the pdgfra gene (such as d842v). 5. the patient has adequate vital organ function, including heart, lungs, liver, kidneys, bone marrow and endocrine, and is expected to tolerate therapy with a tki. 6. patient or legal guardian, if permitted by local regulatory authorities, provides informed consent. exclusion criteria: 1. patients who have poor organ function as defined by one or more of the following laboratory parameters; 1. total bilirubin \> 2 × uln; or \> 3 × uln in the presence of gilbert's disease; 2. platelet count \< 75 × 10\^9/l. 2. patient requires therapy with a concomitant medication that is a strong inhibitor or strong inducer of cytochrome p450 (cyp) 3a4 3. patient has had a major surgical procedure (minor surgical procedures such as central venous catheter placement, tumor needle biopsy, and feeding tube placement are not considered major surgical procedures) within 14 days of the first dose of avapritinib. 4. patient has a history of a cerebrovascular accident or transient ischemic attacks within 1 year prior to the first dose of program drug. 5. patient has a known risk of intracranial bleeding, such as a brain aneurysm or history of subdural or subarachnoid bleeding. 6. women who are unwilling, if not postmenopausal or surgically sterile, to abstain from sexual intercourse or employ highly effective contraception from the time of randomization and for at least 30 days after the last dose of avapritinib. men who are unwilling, if not surgically sterile, to abstain from sexual intercourse or employ highly effective contraception from the time of first dose and for at least 90 days after the last dose of avapritinib. 7. women who are pregnant, as documented by a serum beta human chorionic gonadotropin (β-hcg) pregnancy test consistent with pregnancy, obtained within 7 days before the randomization. females with β-hcg values that are within the range for pregnancy but are not pregnant (false-positives) may be enrolled with written consent of the sponsor, after pregnancy has been ruled out. females of non- childbearing potential (postmenopausal for more than 1 year; bilateral tubal ligation; bilateral oophorectomy; hysterectomy) do not require a serum β-hcg test. 8. women who are breast feeding.
variable perception of cutaneous stimulation

Conditions: Pain, Acute; Anesthesia, Local; Dermatology/Skin - Other

Summary: perception of cutaneous sensory stimulation shows a large range of variability across multiple populations. understanding this variability is critical to medical practice as interpretation of discomfort and pain is critical to diagnosis and treatment. further, procedural medicine involves inflicting pain on patients in the form of injection of local anesthetic. our protocol aims to determine how patients differentially interpret the non-noxious stimulation of vibration and the differences in perceiving anesthestic injection after the vibratory stimulus. we will explore how this ranges across all patients treated in a dermatological surgery out-patient setting. the goal is to identify which variables, such as age, gender, medical history, influence how sensation is interpreted.


Eligibility criteria:
inclusion criteria: * all patients exclusion criteria: * patients less than 18 years of age
comparison of the accuracy in rehabilitation exercise between mobile application actuated rehabilitation exercise guidance and routine rehabilitation exercise guidance for the primary osteoarthritis knee patients

Conditions: Mobile Application Actuated Rehabilitation Exercise Guidance; Routine Rehabilitation Exercise Guidance

Summary: evaluate the accuracy of physical therapy in various positions after 4 weeks of training, comparison of the accuracy in rehabilitation exercise between mobile application actuated rehabilitation exercise guidance and routine rehabilitation exercise guidance for the primary osteoarthritis knee patients


Eligibility criteria:
inclusion criteria: * primary osteoarthritis of knee * have an android phone and use the application exclusion criteria: * there are other complications that may affect physiotherapy * communication problems * has been trained in physical therapy for osteoarthritis patients * have had total knee arthroplasty
pre-pectoral breast reconstruction part 1

Conditions: Breast Cancer

Summary: the rationale for present trial conception and design moves forward from the assumption that a subcutaneous, pre-pectoral reconstruction by means of soft tissue replacement devices is feasible, safe and giving rewarding results when compared to the standard retro-pectoral technique. ahead of that, the trial aims to test if there is a difference in the outcomes between a biological and a synthetic material when placed as a support under the mastectomy skin flaps, both in terms of immediate complications and of long-term results.

this phase iii randomized clinical trial will compare direct-to-implant pre-pectoral breast reconstruction with different supportive materials: the trial will comprise two arms: a-pre-pectoral technique with a biological acellular dermal matrix (adm) prosthesis coverage and support + fat grafting vs b-pre-pectoral technique with a synthetic titanium coated polypropylene mesh (tcpm) prosthesis coverage and support + fat grafting

Eligibility criteria:
inclusion criteria: inclusion criteria will entail cases of conservative mastectomies (skin-sparing mastectomy ssm * nipple-sparing mastectomy nsm and skin-reducing mastectomy srm) * prophylactic and therapeutic. included patients baseline characteristics will be: * age 18-80 years old * bmi between 18.5 and 35. * former smokers (up until 3 weeks before surgery) * hypertension at oral medications * diabetes * previous breast surgery * previous breast and chest wall radiation therapy will be allowed. exclusion criteria: * t4 and metastatic breast cancers * obese patients (bmi over 35) * currently smoking patients (within 3 weeks before surgery) * refusal to sign the consent * severe comorbidities requiring a chronic therapy (renal failure, heart failure, cardiovascular diseases, pulmonary diseases, hepatic diseases, and metabolic diseases).

Keywords: pre-pectoral breast reconstruction subcutaneous breast reconstruction
sorafenib in liver function impaired advanced hepatocellular carcinoma

Conditions: Liver Cancer

Summary: due to the hbv and hcv infection, about 55% hepatocellular carcinoma patients happened in china. among them, only 10% patients can be diagnosed in early stage. sorafenib increased pfs and os in advanced hepatocellular carcinoma patients with liver function of child-pugh class a patients, but the result for child-pugh class b patients is unclear.


Eligibility criteria:
inclusion criteria: * pathological or cytological confirmed advanced hepatocellular carcinoma * 18 years to 80 years * liver function child-pugh class b * bclc stage b or c * estimated life time 2 months or longer exclusion criteria: * previous target therapy * allergy to sorafenib * uncontrolled bleeding or diarrhea * eligible for locoregional treatment

Keywords: sorafenib hepatocellular carcinoma best supportive care survival
randomized double-blind controlled trial of use of dydrogesterone in threatened miscarriage

Conditions: Pregnancy

Summary: the aim of this study is to determine whether the dydrogesterone therapy is associated with reduction in miscarriage in women with first trimester threatened miscarriage. the hypothesis is that the dydrogesterone therapy will significantly reduce the risk of miscarriage in women with threatened miscarriage.


Eligibility criteria:
inclusion criteria: * age of women from 18-40 years at the time of recruitment (not beyond 40th birthday) * absence of fever * gestation less than 12 completed weeks as defined by pelvic ultrasound * presence of intrauterine gestational sac(s) if an urine pregnancy test is first positive within past 2 weeks * presence of intrauterine fetus(es) with crown-rump length of \<7mm and no fetal pulsation, or presence of intrauterine fetus(es) with positive fetal heart pulsation confirmed on pelvic scanning exclusion criteria: * age of women \>40 years at the time of recruitment * history of recurrent miscarriage defined as at least three consecutive spontaneous miscarriages * history of known parental chromosomal abnormalities * heavy vaginal bleeding requiring surgical intervention * severe abdominal pain requiring surgical intervention * absence of cardiac pulsation in a fetal pole with crown-rump length of \>=7mm on transvaginal scanning * use of hcg or progesterone treatment for threatened miscarriage prior to recruitment

Keywords: threatened miscarriage dydrogesterone randomized controlled trial
a human trial to assess the low density lipoprotein cholesterol (ldl-c) lowering effect of soy

Conditions: Hypercholesterolemia; Cardiovascular Disease; CRP

Summary: this study is being conducted to test the hypothesis that daily consumption of a baked food product containing whole soy for 6 weeks will significantly reduce plasma low density lipoprotein cholesterol (ldl-c) in individuals with hypercholesterolemia. as such the overall goals of this study are to determine whether daily consumption of muffins made from whole soy flour for 6 weeks can lower plasma ldl-cholesterol, and if so, establish whether the effect is dose-dependent. to do this, study collaborators will: (1) conduct a detailed chemical and physical characterization of certified defatted whole soy flour that will be incorporated into a muffin; (2) formulate and produce a palatable whole soy flour muffin along with a control muffin containing wheat flour; (3) conduct a parallel controlled trial in which soy muffins will be fed randomly to persons with elevated ldl-cholesterol in a human clinical trial. all participants will be randomized into one of three groups and asked to eat two muffins daily for 6 weeks in the following combination: high dose soy; control group or low dose soy. before, after, and mid-way during the feeding period, blood samples will be obtained for measurements of lipids, glucose, insulin, inflammation, and soy phytochemicals. the effect of soy consumption on waist circumference, body mass index (bmi) and blood pressure will also be examined.


Eligibility criteria:
inclusion criteria: * males and females (not pregnant or lactating) aged 30-70 year * body mass index (bmi) ≤40kg/m² and ≥18.5kg/m² * fasting plasma total cholesterol ≥5.0 * fasting plasma ldl cholesterol ≥3.0 and \<5.0 mmol/l. exclusion criteria: * fasting plasma triglycerides ≥4.0 mmol/l * abnormal liver and kidney function * unstable body weight(\>3kg change in 3 months) or intention to lose or gain weight; * diabetes mellitus (fasting plasma glucose ≥7.0 mmol/l or use of insulin or any hypoglycemic or anti-hyperglycemic medication); * use of any prescription or non-prescription drug, prebiotics or probiotics, herbal or nutritional supplement known to affect blood lipids, except for stable doses (no change in 3 months) of thyroxine, oral contraceptive agents, hormone replacement therapy, and medications for controlling blood pressure); * major surgical or medical events within the past 3 months; * presence of a gastrointestinal disorder or medication that alters the digestion and absorption of nutrients; including antibiotic use within the past 6 weeks. * consumption of a diet containing ≥15% of energy from saturated fat; * any food allergy or aversion or unwillingness to eat wheat, soy or milk; * consumption of ≥5 servings per week of soy based food products; * consumption of an average of \>2 alcoholic beverages per day; * regular smokers (smoking ≥1 cigarette per day) of cigarettes or cigars

Keywords: cholesterol cardiovascular disease soy dose-response
aai in elderly patient with chronic pain

Conditions: Chronic Pain

Summary: background: nowadays, there is a progressive aging of population. chronic osteoarticular pain is associated to a bigger consumption of medication and a deterioration of life quality in elderly people that could be improved by boosting education for health from primary health care. justification: the need to develop non pharmacological treatments in order to get better results in people's global care. purpose: to evaluate the effectivity of group intervention, based on animal assisted therapy, on elderly people suffering from chronic osteoarticular pain and poli-medication; regarding decrease of chronic pain, use of analgesics and improvement of life quality. material and method: randomized clinical trial, two arms, controlled and open-label. twelve group sessions of kinesiotherapy with the intervention of a therapy dog in the experimental group (eg), carried out in the primary health centre.


Eligibility criteria:
inclusion criteria: * ≥65 years * diagnosis of chronic benign joint pain * polypharmacy (\>5 drugs or active ingredients, of which 2 or more had been prescribed for pain) exclusion criteria: * severe cognitive deterioration (gds\> 5) * allergy to or fear of animals

Keywords: animal-assisted therapy chronic pain elderly primary health care